Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 213

1.
2.

The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women.

Barrett-Connor E, Slone S, Greendale G, Kritz-Silverstein D, Espeland M, Johnson SR, Waclawiw M, Fineberg SE.

Maturitas. 1997 Jul;27(3):261-74.

PMID:
9288699
3.

A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.

Baracat EC, Barbosa IC, Giordano MG, Haidar MA, Marinho RM, Menegocci JC, Morais KM, Tomaz G, Wehba S.

Climacteric. 2002 Mar;5(1):60-9. Erratum in: Climacteric 2002 Jun;5(2):vi.

PMID:
11974560
4.

Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study.

Mizunuma H, Okano H, Soda M, Kagami I, Miyamoto S, Tokizawa T, Honjo S, Ibuki Y.

Maturitas. 1997 May;27(1):69-76.

PMID:
9158080
5.

Dose response effect of cyclical medroxyprogesterone on blood pressure in postmenopausal women.

Harvey PJ, Molloy D, Upton J, Wing LM.

J Hum Hypertens. 2001 May;15(5):313-21.

6.

Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.

Barnabei VM, Cochrane BB, Aragaki AK, Nygaard I, Williams RS, McGovern PG, Young RL, Wells EC, O'Sullivan MJ, Chen B, Schenken R, Johnson SR; Women's Health Initiative Investigators.

Obstet Gynecol. 2005 May;105(5 Pt 1):1063-73.

PMID:
15863546
7.

Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators.

Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, Bassett LW, Wasilauskas C, Bush T, Barrett-Connor E.

Ann Intern Med. 1999 Feb 16;130(4 Pt 1):262-9.

PMID:
10068383
8.
9.

Postmenopausal hormone therapy and change in mammographic density.

Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G.

J Natl Cancer Inst. 2003 Jan 1;95(1):30-7.

10.
11.

Effects of continuous combined hormone replacement therapy on inflammation in hypertensive and/or overweight postmenopausal women.

Koh KK, Ahn JY, Jin DK, Yoon BK, Kim HS, Kim DS, Shin MS, Son JW, Choi IS, Shin EK.

Arterioscler Thromb Vasc Biol. 2002 Sep 1;22(9):1459-64.

13.

Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.

Gordon S, Walsh BW, Ciaccia AV, Siddhanti S, Rosen AS, Plouffe L Jr.

Obstet Gynecol. 2004 Feb;103(2):267-73.

PMID:
14754694
16.

Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial.

Greendale GA, Reboussin BA, Hogan P, Barnabei VM, Shumaker S, Johnson S, Barrett-Connor E.

Obstet Gynecol. 1998 Dec;92(6):982-8.

PMID:
9840563
17.
18.

Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women.

Koh KK, Jin DK, Yang SH, Lee SK, Hwang HY, Kang MH, Kim W, Kim DS, Choi IS, Shin EK.

Circulation. 2001 Apr 17;103(15):1961-6.

19.
Items per page

Supplemental Content

Write to the Help Desk